Company Insights

ECOR customer relationships

Explore interactive graphBrowse insights index
ECOR customer relationship map

Electrocore (ECOR): Customer Map and What It Means for Revenue Stability

Electrocore develops and commercializes non‑invasive vagus nerve stimulation devices (gammaCore and the consumer Truvaga line) and monetizes through product sales into two distinct channels: large, long‑term government contracts (especially the U.S. VA and UK NHS) for prescribed therapeutic use, and broader retail and distribution channels for consumer and DME sales. The company’s top-line growth is driven by deep government penetration that delivers concentrated, recurring revenue while management is pursuing diversification into consumer retail and specialty clinic research to reduce concentration risk. For investors, the question is simple: is the government anchor sustainable and can retail/distribution scale materially without undermining margins?
For a deeper operational risk view, visit https://nullexposure.com/.

How the operating model actually works and what that implies

Electrocore operates with a bifurcated selling posture. On one hand, long‑term framework contracting under Federal Supply Schedule (FSS) and analogous public procurement provides predictable large orders and channel access into the VA and other government systems. Company filings describe FSS extensions and follow‑on offers that sustain VA sales. On the other hand, the firm is expanding into open market DME distributors and consumer retail placements (Best Buy, Rehabmart, affiliate marketing partners) to capture incremental volume and brand awareness.

These characteristics create clear constraints for investors:

  • Contracting posture: long‑term framework exposure. Electrocore’s revenue base relies heavily on extended FSS arrangements and other contracting mechanisms that create durable but procurement‑sensitive sales flows. The company disclosed FSS modifications and term extensions through mid‑2025 while a replacement offer was under review.
  • Concentration risk: highly VA‑dependent but with deliberate diversification attempts. The VA accounted for 70.6% of revenue in 2024, making the relationship critical to financial stability; UK NHS funding accounted for a material but much smaller share (single‑digit percent via the MTFM for cluster headache).
  • Geography: U.S.‑weighted with EMEA pockets. Reported revenue runs strongly in North America with specific EMEA exposure driven by NHS programs.
  • Relationship maturity and role: seller with active commercial engagement. The company reports ongoing sales through government channels and through DME/retail partners, indicating active, transactional relationships rather than one‑off pilots.
  • Spend band signal: company disclosures show VA channel revenue in the multi‑million range and FSS mechanics that imply material government spend bands for procurement planning.

Together these signals create a revenue profile that is predictable but concentrated, and where incremental upside depends on successful retail scaling and clinic/research adoption. Learn more about the implications for procurement‑centric business models at https://nullexposure.com/.

The customer and partner list — who matters today

Below are every customer/partner mention found in the company’s public results and filings, with plain‑English summaries and source references.

VA hospital system

The VA is Electrocore’s largest and most material customer, accounting for over 70% of revenue in 2024 and supplied under the Federal Supply Schedule and open market VA facility sales. According to the company’s Q3 2025 earnings call, the VA “remains our largest customer and continues to grow.” (Q3 2025 earnings call)

Best Buy (BBY)

Electrocore is moving consumer product placement into mainstream retail: management said Truvaga will be available through Best Buy, indicating a deliberate push to capture consumer demand beyond clinical channels. (Q3 2025 earnings call)

Rehabmart

Rehabmart is named alongside Best Buy as an online retail placement for Truvaga, representing an e‑commerce channel to reach DME and consumer buyers beyond healthcare procurement. (Q3 2025 earnings call)

TruMed

Affiliates such as TruMed are active promoters of Truvaga, providing influencer/distribution support as Electrocore expands consumer access; management lists TruMed as one of the affiliates promoting the product. (Q3 2025 earnings call)

Joerns

Joerns is a DME distributor that added gammaCore Sapphire to a managed care contract, signaling traction in institutional DME procurement and broader access to facilities that source through distributors. (Q3 2025 earnings call)

NeuroMetrix (NURO)

NeuroMetrix was acquired by Electrocore (closing May 1, 2025), bringing the Quell platform into the company and enabling early traction for Quell as a noninvasive pain therapeutic within the VA system. Management referenced the NeuroMetrix acquisition and its Quell product showing early traction in the VA during the Q3 2025 call. (Q3 2025 earnings call; press release on the NeuroMetrix acquisition, May 2025)

Acacia Clinics

Acacia Clinics is a clinical partner running a study using gammaCore Sapphire as an adjunctive PTSD treatment, indicating institutional research adoption that can support clinical claims and payer acceptance. This initiative was disclosed in a Globenewswire release announcing the study collaboration. (GlobeNewswire press release, Jan 21, 2026)

Vagus Nerve Society

The Vagus Nerve Society is sponsoring the PTSD adjunctive study and Electrocore is providing an educational grant and devices, reflecting research and KOL engagement to validate new indications for gammaCore. (GlobeNewswire press release, Jan 21, 2026)

What investors should take away — risks and the roadmap

  • Revenue concentration is the single largest risk. The VA accounted for 70.6% of 2024 revenue; this is explicitly material and creates exposure to procurement cycles and contract renewals. (Company filings and disclosures for 2024)
  • Contractual posture is defensive and steady. FSS and other framework relationships deliver recurring orders and a predictable cadence, but they limit price flexibility and tie revenue to government procurement timelines; management disclosed FSS modifications extending coverage into 2025 while a replacement contract was reviewed. (Company disclosures on FSS, through mid‑2025)
  • Diversification is deliberate but early. Retail placements (Best Buy, Rehabmart), DME distributor wins (Joerns), acquisitions (NeuroMetrix/Quell), and sponsored research (Acacia/Vagus Nerve Society) create multiple paths to reduce VA dependence — but these are complementary growth engines rather than immediate replacements.
  • Clinical validation and payer acceptance matter. Research sponsorships and specialist society engagement improve the probability of broader reimbursement and clinical adoption, which are essential to move beyond government procurement.

If you evaluate supplier concentration, procurement dependency, and go‑to‑market diversification for med‑tech investing, this customer map is a concise read for decision makers. Explore similar customer relationship intelligence at https://nullexposure.com/.

Final recommendation and next steps

Electrocore is a procurement‑anchored commercial med‑tech with a concentration that both stabilizes near‑term revenue and creates execution risk if government spend patterns change. For investors who value predictable government flows and optionality from retail/clinical expansion, ECOR offers an asymmetric play: downside tied to procurement concentration, upside in scaling consumer and research adoption.

For a structured review of supplier concentration and procurement risk across portfolios, visit https://nullexposure.com/ for tailored analysis and investor briefings.